轻型缺血性卒中TOAST分型及静脉溶栓的研究

Abstract
Figure/Table
References (19)
Related Citation (0)

Download: PDF (406 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analysis safety and short-term prognosis of rt-PA intravenous thrombolysis treatment in different TOAST subtype of minor ischaemic stroke. Methods From November 2013 to January 2016, 256 patients with mild ischaemic stroke in Chengde Central Hospital were selected. 136 patients were treated with rt-PA intravenous thrombolysis (intravenous thrombolysis group), and 120 patients were treated with oral drugs (non thrombolysis group), the patients in the two groups were divided by TOAST etiology. 90 days after treatment, the scores of NIHSS and mRS, the cerebral hemorrhage rate, death rate, recurrence rate were observed, besides the NIHSS score of 0-1 and mRS of 0-1 were defined as good outcomes. Results The proportion of good outcomes in the intravenous thrombolysis group was higher than that of the non thrombolysis group, the recurrence rate was lower than that of the non thrombolysis group, with statistically significant difference (P < 0.05). And the proportion of good outcomes in the LAA subgroup who were treated with rt-PA intravenous thrombolysis was higher and the recurrence rate was lower (P < 0.05). Conclusion rt-PA intravenous thrombolysis can improve the proportion of good outcomes in the patients with minor ischaemic stroke in 90 days, especially LAA subtype, reduce the recurrence rate, and it has good safety.

Key words： Minor ischaemic stroke Recombinant tissue plasminogen activator Thrombolytic therapy TOAST etiology

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Haibao YANG Jing SHEN Yongling QI Limin FENG Li ZHANG Guanwen SANG Xiaoyi CHENG Ruinian

Cite this article:

ZHU Haibao YANG Jing SHEN Yongling QI Limin FENG Li ZHANG Guanwen SANG Xiaoyi CHENG Ruinian. The study of intravenous thrombolysis for different TOAST subtype of minor ischaemic stroke[J]. 中国医药导报, 2017, 14(23): 56-59.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I23/56

[1] Barber PA，Zhang J，Demchuk AM，et al. Why are stroke?鄄patients excluded from TPA therapy？An analysis of patient eligibility [J]. Neurology，2001，56（8）：1015-1020.
[2] 姬海超，闫福岭.轻型脑梗死的溶栓治疗[J].中华脑血管病杂志，2012，6（5）：239-245.
[3] Yeo LL，Ho R，Paliwal P，et al. Intravenously administered tissue plasminogen activator useful in milder strokes？A meta-analysis [J]. J Stroke Cerebrovasc Dis，2014，23（8）：2156-2162.
[4] Greisenegger S，Seyfang L，Kiechl S，et al. Thrombolysis in patients with mild stroke：results from the Austrian Stroke Unit Registry [J]. Stroke，2014，45（3）：765-769.
[5] Logallo N，Kvistad CE，Naess H，et al. Mild stroke：safety and outcome in patients receiving thrombolysis [J]. Acta Neurol Scand Suppl，2014，129（198）：37-40.
[6] Huisa BN，Raman R，Neil W，et al. Intravenous tissue plasminogen activator for patients with minor ischemic stroke [J]. J Stroke Cerebrovasc Dis，2012，21（8）：732-736.
[7] Frank B，Grotta JC，Alexandrov AV，et al. Thrombolysis in stroke despite contraindications or warnings？[J] Stroke，2013，44（3）：727-733.
[8] Sandercock P，Wardlaw JM，Lindley RI，et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke （the third international stroke trial [IST-3]）：a ran?鄄domised controlled trial [J]. Lancet，2012，379（9834）：2352-2363.
[9] Adams HP Jr，Bendixen BH，Kappelle LJ，et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment [J]. Stroke，1993，24（1）：35-41.
[10] Hacke W，Kaste M，Bluhmki E，et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke [J]. N Engl J Med，2008，359（13）：1317-1329.
[11] National Institute of Neurological Disorders Stroke rt-PASS Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes：the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience [J]. Ann Emerg Med，2005，46（2）：243-252.
[12] Fischer U，Baumgartner A，Arnold M，et al. What is a minor stroke？[J]. Stroke，2010，41（4）：661-666.
[13] Reeves M， Khoury J， Alwell K， et al. Distribution of National Institutes of Health stroke scale in the Cincinnati/Northern Kentucky Stroke Study[J]. Stroke. 2013， 44（11）：3211-3213.
[14] Smith EE，Fonarow GC， Reeves MJ，et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator：findings from get with the guidelines-stroke [J]. Stroke，2011，42（11）：3110-3115.
[15] Khatri P，Conaway MR，Johnston KC. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke [J]. Stroke，2012，43（2）：560-562.
[16] Nedeltchev K，Schwegler B，Haefeli T，et al. Outcome of stroke with mild or rapidly improving symptoms [J]. Stroke，2007，38（9）：2531-2535.
[17] Choi JC，Jang MU，Kang K，et al. Comparative effectiveness of standard care with Ⅳthrombolysis versus without Ⅳ thrombolysis for mild ischemic stroke [J]. J Am Heart Assoc，2015，4（1）：e001306.
[18] Khatri P，Kleindorfer DO，Yeatts SD，et al. Strokes with minor symptoms：an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials [J]. Stroke，2010，41（11）：2581-2586.
[19] Hassan AE，Zacharatos H，Hassanzadeh B，et al. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator？[J]. J Stroke Cerebrovasc Dis，2010，19（2）：116-120.